Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccination and SARS-CoV-2 infection monitoring in Stockholm healthcare workers
2021-000206-17Phase 4Active
- Sponsor
- Karolinska University Hospital
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of elasomeran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Karolinska University Hospital. Primary endpoints: Detection of SARS-CoV-2 infection relative to vaccination status, Characterization of asymptomatic versus sick leave-requiring infection and 1 more. Started Feb 2021; status: active.
02
Drugs
elasomeranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000206-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000206-17.